drugset / Trial / NCT00927472

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00927472 ↗

Phase 3 Completed 254 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-06

Outcome

Met primary endpoint

registry analysis (superiority or other test); Malathion Gel vs Nix Creme Rinse; p = 0.0386; t-test, 2 sided NCT00927472 ↗

registry analysis (superiority or other test); Malathion Gel vs Nix Creme Rinse; p = 0.0490; t-test, 2 sided NCT00927472 ↗

registry analysis (superiority or other test); Malathion Gel vs Nix Creme Rinse; p = 0.0002; t-test, 2 sided NCT00927472 ↗

registry analysis (superiority or other test); Malathion Gel vs Nix Creme Rinse; p = 0.0003; t-test, 2 sided NCT00927472 ↗

registry analysis (superiority or other test); Malathion Gel vs Nix Creme Rinse; p = 0.0012; t-test, 2 sided NCT00927472 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Malathion Small molecule 0.5 % Topical
Comparator Permethrin Small molecule 1 % Topical